Pancreatic adenosquamous carcinoma
Clinical trials for Pancreatic adenosquamous carcinoma explained in plain language.
Never miss a new study
Get alerted when new Pancreatic adenosquamous carcinoma trials appear
Sign up with your email to follow new studies for Pancreatic adenosquamous carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 13:01 UTC
-
New pill plus chemo takes on deadly pancreatic cancer in huge trial
Disease control Recruiting nowThis phase 3 trial tests a new drug called daraxonrasib, taken as a pill, either alone or with standard chemotherapy, against chemotherapy alone for people with metastatic pancreatic cancer. About 900 adults with confirmed pancreatic cancer that has spread will be randomly assign…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a pill duo outsmart a Hard-to-Treat pancreatic cancer mutation?
Disease control Recruiting nowThis phase 3 trial compares a combination of two experimental oral drugs, zoldonrasib and daraxonrasib, against standard chemotherapy (gemcitabine plus nab-paclitaxel) as the first treatment for people with metastatic pancreatic cancer that has a specific KRAS G12D mutation. The …
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a Patient's own immune cells be trained to fight pancreatic cancer?
Disease control Recruiting nowThis early-stage trial is testing whether a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy, is safe and feasible for treating pancreatic cancer after surgical removal. The vaccine is designed to train the immune system to recogniz…
Matched conditions: PANCREATIC ADENOSQUAMOUS CARCINOMA
Phase 1 • Sponsor: Diakonos Oncology Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC